The FDA needs to set standards for using artificial intelligence in drug development
Author
Charles K. Fisher
Published
November 7, 2019
Opinion: Poorly constructed AI algorithms for drug discovery and testing have the potential to cause harm. The FDA should play an important role in ensuring that AI-based drug development tools meet appropriate standards.
Next-gen digital health innovation in clinical trials
December 8, 2020
The Rock Health team reflects on the evolution of digital in clinical trials, discuss the current state, and explore the opportunity to further transform drug discovery.
